All In Biotech

Drug Trial Radar · NCT07023614

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy - FORTITUDE-HCM

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Oct 6, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Imbria Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM

Conditions

  • Non-obstructive Hypertrophic Cardiomyopathy

Interventions

  • Ninerafaxstat 200mg MRDrug

    Ninerafaxstat 200mg Modified Release tablet administered BID

  • PlaceboDrug

    Matching placebo tablet administered BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)Time frame: Baseline to Week 12

Locations

76 sites in 11 countries. Site status is shown where the registry gives one.

  • Imbria Investigational Site

    La Jolla, California · Recruiting

  • Imbria Investigational Site

    Los Angeles, California · Recruiting

  • Imbria Investigational Site

    San Francisco, California · Recruiting

  • Imbria Investigational Site

    Washington D.C., District of Columbia · Recruiting

  • Imbria Investigational Site

    Miami, Florida · Recruiting

  • Imbria Investigational Site

    Atlanta, Georgia · Not yet recruiting

  • Imbria Investigational Site

    Chicago, Illinois · Recruiting

  • Imbria Investigational Site

    Oak Lawn, Illinois · Not yet recruiting

  • Imbria Investigational Site

    Baltimore, Maryland · Recruiting

  • Imbria Investigational Site

    Boston, Massachusetts · Recruiting

  • Imbria Investigational Site

    Burlington, Massachusetts · Recruiting

  • Imbria Investigational Site

    Grand Rapids, Michigan · Recruiting

  • Imbria Investigational Site

    Rochester, Minnesota · Recruiting

  • Imbria Investigational Site

    St Louis, Missouri · Recruiting

  • Imbria Investigational Site

    New York, New York · Recruiting

  • Imbria Investigational Site

    New York, New York · Not yet recruiting

  • Imbria Investigational Site

    Charlotte, North Carolina · Recruiting

  • Imbria Investigational Site

    Portland, Oregon · Recruiting

  • Imbria Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • Imbria Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • Imbria Investigational Site

    Houston, Texas · Recruiting

  • Imbria Investigational Site

    Houston, Texas · Not yet recruiting

  • Imbria Investigational Site

    Plano, Texas · Recruiting

  • Imbria Investigational Site

    Salt Lake City, Utah · Not yet recruiting

  • Imbria Investigational Site

    Charlottesville, Virginia · Recruiting

  • Imbria Investigational Site

    Richmond, Virginia · Recruiting

  • Imbria Investigational Site

    Milwaukee, Wisconsin · Not yet recruiting

  • Imbria Investigational Site

    Graz, Austria · Recruiting

  • Imbria Investigational Site

    Edegem, Belgium · Recruiting

  • Imbria Investigational Site

    Montpellier, France · Recruiting

  • Imbria Investigational Site

    Paris, France · Recruiting

  • Imbria Investigational Site

    Saint-Herblain, France · Recruiting

  • Imbria Investigational Site

    Bad Oeynhausen, Germany · Recruiting

  • Imbria Investigational Site

    Göttingen, Germany · Recruiting

  • Imbria Investigational Site

    Heidelberg, Germany · Recruiting

  • Imbria Investigational Site

    Jena, Germany · Not yet recruiting

  • Imbria Investigational Site

    Bologna, Italy · Not yet recruiting

  • Imbria Investigational Site

    Florence, Italy · Recruiting

  • Imbria Investigational Site

    Massa, Italy · Recruiting

  • Imbria Investigational Site

    Milan, Italy · Recruiting

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.